Hemab Therapeutics opens at $27, IPO priced at $18 per share

Hemab Therapeutics (COAG) priced 16.75M shares at $18.00. The deal size was increased to 16.75M shares from 15.0M and priced at the top end of the $16.00-$18.00 target range. Goldman Sachs, Jefferies and Evercore ISI are acting as joint book running managers for the offering. Hemab Therapeutics is a clinical-stage biotechnology company developing therapies that it says “reimagine the treatment of blood coagulation disorders to sustain life and human resilience.”